No insider purchase over the last 90 days. The latest, by Rajesh Jain, was filed 24 Jul 2026.
Every trade that managers of Panacea Biotec Limited disclose to SEBI (PIT + SAST) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 24 October 2026, 5 filings were filed, from 5 insiders.
Open-market activity splits into 2 purchases and 1 sale totalling €11k; 2 insiders sit on the buying side and 1 insider on the selling side. The totals exclude 2 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants. Nosheen Sheikh filed the largest sale, €11k, on 25 August 2026, which represents 0.0052% of the company's market value.
With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,891 companies we follow on the same exchange. The full history, which starts in 2023, counts 4 purchases against 34 sales.
The last purchase on record was published on 24 July 2026, which is 92 days ago. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. Until a filing is published, the market cannot know about the trade.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
25 of 48 declarations
Panacea Biotec Limited is a company focused on the healthcare and pharmaceutical sector, providing innovative biopharmaceutical solutions. It is listed on the XBOM.
Purchases our model currently ranks for the recommendations list.
All recommendations